For the quarter ending 2025-09-30, ABVC had -$222,415 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Loss on investment in equity securities | - | -95,794 |
| Net loss | -1,287,523 | -3,277,023 |
| Depreciation | 5,821 | 13,718 |
| Stock-based compensation | 1,136,217 | 1,620,386 |
| Other non-cash expenses | 25,963 | 317,279 |
| Loss on investment in equity securities | -150,029 | - |
| Amortization of right-of-use asset | 90,190 | 181,062 |
| Inventories | 0 | 11,460 |
| Prepaid expenses and other current assets | 2,281 | 73,786 |
| Due from related parties | -20,598 | 190,394 |
| Accrued expenses and other current liabilities | -33,632 | 23,248 |
| Tenant security deposit | -29,575 | 24,710 |
| Taxes payables | -17,351 | 23,521 |
| Operating lease liabilities | -95,919 | -181,062 |
| Net cash used in operating activities | -133,257 | -1,434,007 |
| Loan to affiliates | 1,271,112 | 808,240 |
| Prepayment from related parties | 3,176 | 142,461 |
| Transaction costs for land acquisition | 5,421 | - |
| Proceeds from issuance of warrants | - | 0 |
| Net cash used in investing activities | -1,273,357 | -665,779 |
| Proceeds from private placements | 908,370 | 1,868,750 |
| Proceeds from exercise of warrants | 579,699 | 411,667 |
| Proceeds from convertible notes payable | 0 | 9,010 |
| Repayment of convertible notes payable | 277,284 | - |
| Proceeds from common stock subscription | - | 170,000 |
| Proceeds from convertible notes payable - related party | 150,000 | - |
| Proceeds from short-term loans | - | 0 |
| Repayment of short-term loans | 31,406 | 58,875 |
| Proceeds from short-term bank loans | - | 0 |
| Due to related parties, net | -26,984 | -44,469 |
| Net cash provided by financing activities | 1,132,395 | 2,356,083 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 51,804 | -43,786 |
| Net decrease in cash and cash equivalents and restricted cash | -222,415 | 212,511 |
| Cash and cash equivalents at beginning of period | 863,815 | - |
| Cash and cash equivalents at end of period | 853,911 | - |
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)